The Fact.MR market study on the pediatric neuroblastoma treatment market provides deep dive into key developments in the pediatric neuroblastoma treatment market.
Increasing Prevalence of Cancers Worldwide is Expected to Drive the Pediatric Neuroblastoma Treatment Market Growth
The Fact.MR market study on the pediatric neuroblastoma treatment market provides deep dive into key developments in the pediatric neuroblastoma treatment market. The report offers a comprehensive analysis of leading segments in terms of therapy type, distribution channel, and region.
Fact.MR – A Market research and competitive intelligence provider: The global pediatric neuroblastoma treatment market size is expected to surge at a staggering CAGR of 9.2% throughout the forecast period (2020-2026).
The increasing burden of the condition is expected to push demand for treating the disease. With the ongoing COVID-19 pandemic healthcare workers are exercising caution and stepping up treatment to protect cancer-afflicted children from infection.
The presence of a large number of pharmaceutical and biotechnology companies focusing on neuroblastoma research and a rise in the growth of healthcare awareness are also projected to leverage the European market. The European market is set to capture nearly a quarter of the global pediatric neuroblastoma treatment market.
For Critical Insights on This Market, Request for More Info
https://www.factmr.com/connectus/sample?flag=S&rep_id=4694
Neuroblastoma is amongst the most common cancers affecting infants under the age of one. The condition accounts for nearly 6% of the market share of all cancers in children, especially in developed countries such as the United States. Also, an estimated 800 new cases of neuroblastoma are reported annually in the U.S.
Most childhood cancers have an aggressive course and require immediate treatment, often involving prolonged durations of intensive multi-agent chemotherapy.
Reduction in cancer growth and bearability of symptoms, and in certain cases, complete eradication of cancers are projected to drive the segment’s growth.
Key Takeaways:
- North America shall dominate the global pediatric neuroblastoma treatment market size growing at an impressive CAGR of 9.0% and capturing over half of the market share.
- Europe is poised to register the fastest growth in the global pediatric neuroblastoma treatment market as increasing incidences of neuroblastoma and rising drug approvals are attributed as important growth levers.
- By therapy type, the chemotherapy segment is expected to account for more than half of the pediatric neuroblastoma treatment market share. It is also projected CAGR for the segment at 9.2% during the forecast period.
- By distribution channel, hospitals shall continue dominating the global pediatric neuroblastoma market, capturing more than three-fifths of the market share in the pediatric neuroblastoma treatment market
Growth Drivers:
- Increasing designation of orphan drugs for treating cancer patients such as neuroblastoma is expected to drive the growth of the global pediatric neuroblastoma treatment market.
- Demand in the sales of chemotherapy products for neuroblastoma, such as cyclophosphamide, carboplatin, and Doxorubicin are found to significantly improve the health conditions of children as it will also drive the growth of the global pediatric neuroblastoma treatment market.
To gain in-depth insights on the Pediatric Neuroblastoma Treatment Market, request methodology at:
https://www.factmr.com/connectus/sample?flag=RM&rep_id=4694
Competitive Landscape:
The competitive landscape of the Pediatric Neuroblastoma Treatment Market focuses on attributing to a shortage in the workforce within organizations and increased work-from-home directives.
- Cellectar Biosciences received orphan drug designation from the U.S. FDA for its CLR 131 Phospholipid Drug Conjugate (PDC) to treat pediatric neuroblastoma patients in early 2018.
- The drug is currently in Stage 1 of development. The global pediatric neuroblastoma treatment market is anticipated to surge at a staggering CAGR of 9.2% throughout the forecast period (2020-2026).
Key Companies Profiled by Fact.MR
- United Therapeutics Corporation
- APEIRON Biologics AG
- Baxter
- Bayer AG
- Pfizer Inc.
More valuable insights on the Pediatric Neuroblastoma Treatment Market:
Fact.MR, in its report, offers a market analysis of the global Pediatric Neuroblastoma Treatment Market the forecast period through 2020 and beyond. This survey reveals the growth of sports in the Pediatric Neuroblastoma Treatment Market with detailed segmentation as follows
Therapy-type
- Immunotherapy
- Chemotherapy
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies & Drug Stores
Region
- North America
- Europe
- Rest of the World
Key Questions covered in the Pediatric Neuroblastoma Treatment Market Report
- The report offers insight into the Pediatric Neuroblastoma Treatment Market demand outlook for 2020-2026
- The market study also highlights projected sales growth for the Pediatric Neuroblastoma Treatment Market between 2020 and 2026
- Pediatric Neuroblastoma Treatment Market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
- Pediatric Neuroblastoma Treatment Market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others
Explore Fact.MR’s Coverage on the Healthcare Domain-
Cancer Therapeutics Market Forecast - Discoveries of revolutionary peptide-based medications are projected to influence developing trends in the cancer therapeutics market, with the cancer therapeutics sector is steady in its R&D operations. In the future years, peptide-based drugs are projected to become more widely used in cancer therapeutics.
Cancer Biomarkers Market Analysis - Governments' aggressive funding initiatives for cancer diagnostics are expanding the market for cancer biomarkers. Demand for cancer biomarkers will be bolstered by factors such as the availability of low-cost, non-invasive prognosis.
Cancer Profiling Market Scope - The global cancer profiling market is predicted to grow significantly between now and 2021, as the demand for precision medicine and high-quality oncology care grows.
Early-Stage Lung Cancer Diagnostics Market Insights - Increasing prevalence of leukemia and prostate cancer with increased funding by governments for the development of novel therapies for the treatment of cancer to drive the early-stage lung cancer diagnostics market.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have in our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & chemical and materials, our coverage is expansive, but we ensure even the most niche categories are analysed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Source: Fact.MR